차세대 시퀀싱 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 제품별, 용도별, 워크플로우별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Next Generation Sequencing Market Summary

The global next-generation sequencing market size was estimated at USD 11.26 billion in 2025 and is projected to reach USD 42.25 billion by 2033, growing at a CAGR of 18.00% from 2026 to 2033. This growth is driven by the increasing demand for advanced genomic research, rising applications of NGS in clinical diagnostics, and ongoing technological advancements in sequencing platforms.

Global Next Generation Sequencing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global next-generation sequencing market report based on the technology, product, workflow, end use, and region:

• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• WGS
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing
  • DNA-based
  • RNA-based
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Platform
  • Sequencing
  • Data Analysis
• Consumables
  • Sample Preparation
  • Target Enrichment
  • Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
  • Diagnostics and Screening
  • Oncology Screening
  • Sporadic Cancer
  • Inherited Cancer
  • Companion Diagnostics
  • Other Diagnostics
  • Research Studies
• Clinical Investigation
  • Infectious Diseases
  • Inherited Diseases
  • Idiopathic Diseases
  • Non-Communicable/Other Diseases
• Reproductive Health
  • NIPT
  • Aneuploidy
  • Microdeletions
  • PGT
  • Newborn Genetic Screening
  • Single Gene Analysis
• HLA Typing/Immune System Monitoring
• Metagenomics, Epidemiology & Drug Development
• Agrigenomics & Forensics
• Consumer Genomics
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Pre-Sequencing
  • Nucleic Acid Extraction
  • Library Preparation
• Sequencing
• NGS Data Analysis
  • NGS Primary Data Analysis
  • NGS Secondary Data Analysis
  • NGS Tertiary Data Analysis
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharma & Biotech Entities
• Other Users
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Technology Segment
  • 1.1.2. Product Segment
  • 1.1.3. Workflow Segment
  • 1.1.4. Application Segment
  • 1.1.5. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objective
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, and Trends

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Market Drivers Analysis
    • 3.4.1.1. Decreasing costs for genetic sequencing
    • 3.4.1.2. Development of companion diagnostics and personalized medicine
    • 3.4.1.3. Rising clinical opportunity for NGS technology
    • 3.4.1.4. Technological advancements in cloud computing
  • 3.4.2. Market Restraint Analysis
    • 3.4.2.1. Lack of computational efficiency for data management
    • 3.4.2.2. Non-value-based NGS reimbursement policy and regulation status
    • 3.4.2.3. Challenges associated with NGS implementation
• 3.5. Market Analysis Tools
  • 3.5.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
  • 3.5.2. Porter's Five Forces Analysis

Chapter 4. Technology Business Analysis

• 4.1. Segment Dashboard
• 4.2. Next Generation Sequencing Data Analysis Market: Technology Movement Analysis
• 4.3. Targeted Sequencing & Resequencing
  • 4.3.1. Targeted Sequencing & Resequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 4.3.2. DNA-Based Targeted Sequencing & Resequencing
    • 4.3.2.1. DNA-based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • 4.3.3. RNA-Based Targeted Sequencing & Resequencing
    • 4.3.3.1. RNA -based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
• 4.4. Whole Genome Sequencing
  • 4.4.1. Whole Genome Sequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 4.5. Whole Exome Sequencing
  • 4.5.1. Whole Exome Sequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 5. Product Business Analysis

• 5.1. Segment Dashboard
• 5.2. Next Generation Sequencing Data Analysis Market: Product Movement Analysis
• 5.3. Platforms
  • 5.3.1. Platforms Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.3.2. Sequencing
    • 5.3.2.1. Sequencing Platforms Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.3.3. Data Analysis
    • 5.3.3.1. Data Analysis Platforms Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 5.4. Consumables
  • 5.4.1. Consumables Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.4.2. Sample Preparation
    • 5.4.2.1. Sample Preparation Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.4.3. Target Enrichment
    • 5.4.3.1. Target Enrichment Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Others Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Segment Dashboard
• 6.2. Next Generation Sequencing Data Analysis Market: Application Movement Analysis
• 6.3. Oncology
  • 6.3.1. Oncology Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.3.2. Diagnostics & Screening
    • 6.3.2.1. Diagnostics & Screening Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 6.3.2.2. Oncology screening
      • 6.3.2.2.1. Oncology Screening Market Estimates and Forecast, 2021 - 2033 (USD Million)
      • 6.3.2.2.2. Sporadic Cancer Screening Market Estimates and Forecast, 2021 - 2033 (USD Million)
      • 6.3.2.2.3. Inherited Cancer Screening Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 6.3.2.3. Companion diagnostics
      • 6.3.2.3.1. Companion Diagnostics Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 6.3.2.4. Other Diagnostics
      • 6.3.2.4.1. Other Diagnostics Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.3.3. Research Studies
    • 6.3.3.1. Research Studies Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.4. Clinical Investigation
  • 6.4.1. Clinical Investigation Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.4.2. Infectious Diseases
    • 6.4.2.1. Infectious Diseases Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.4.3. Idiopathic Diseases
    • 6.4.3.1. Idiopathic Diseases Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.4.4. Inherited Diseases
    • 6.4.4.1. Inherited Diseases Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.4.5. Non-communicable/other Diseases
    • 6.4.5.1. Reproductive Health Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.5. Reproductive Health
  • 6.5.1. Clinical Investigation Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.5.2. NIPT
    • 6.5.2.1. NIPT Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 6.5.2.2. Aneuploidy
      • 6.5.2.2.1. Aneuploidy Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 6.5.2.3. Microdeletions
      • 6.5.2.3.1. Microdeletions Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.5.3. PGT
    • 6.5.3.1. PGT Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.5.4. Newborn Genetic Screening
    • 6.5.4.1. Newborn Genetic Screening Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.5.5. Single Gene Analysis Market
    • 6.5.5.1. Single Gene Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.6. HLA Typing/Immune System Monitoring
  • 6.6.1. HLA Typing/Immune System Monitoring Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.7. Metagenomics, Epidemiology & Drug Development
  • 6.7.1. Metagenomics, Epidemiology & Drug Development Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.8. Agrigenomics & Forensics
  • 6.8.1. Agrigenomics & Forensics Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.9. Consumer Genomics
  • 6.9.1. Consumer Genomics Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 7. Workflow Business Analysis

• 7.1. Segment Dashboard
• 7.2. Next Generation Sequencing Data Analysis Market: Workflow Movement Analysis
• 7.3. Presequencing
  • 7.3.1. Presequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.3.2. Nucleic Acid Extraction
    • 7.3.2.1. Nucleic Acid Extraction Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.3.3. Library Preparation
    • 7.3.3.1. Library Preparation Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 7.4. Sequencing
  • 7.4.1. Sequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 7.5. Data Analysis
  • 7.5.1. Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.5.2. Primary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 7.5.2.1. Primary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.5.3. Secondary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 7.5.3.1. Secondary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.5.4. Tertiary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 7.5.4.1. Tertiary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 8. End - Use Business Analysis

• 8.1. Segment Dashboard
• 8.2. Next Generation Sequencing Market: End - Use Movement Analysis
• 8.3. Academic Research
  • 8.3.1. Academic Research Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 8.4. Clinical Research
  • 8.4.1. Clinical Research Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 8.5. Hospitals & Clinics
  • 8.5.1. Hospitals & Clinics Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 8.6. Pharmaceutical & Biotech Entities
  • 8.6.1. Pharmaceutical & Biotech Entities Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 8.7. Other Users
  • 8.7.1. Other Users Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 9. Regional Business Analysis

• 9.1. Next Generation Sequencing Market Share, By Region, 2025 & 2033
• 9.2. North America
  • 9.2.1. North America next generation sequencing market, 2021 - 2033 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key country dynamics
    • 9.2.2.2. U.S. next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.2.3. Target disease prevalence
    • 9.2.2.4. Competitive scenario
    • 9.2.2.5. Regulatory framework
    • 9.2.2.6. Reimbursement scenario
  • 9.2.3. Canada
    • 9.2.3.1. Key country dynamics
    • 9.2.3.2. Canada next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.3.3. Target disease prevalence
    • 9.2.3.4. Competitive scenario
    • 9.2.3.5. Regulatory framework
    • 9.2.3.6. Reimbursement scenario
  • 9.2.4. Mexico
    • 9.2.4.1. Key country dynamics
    • 9.2.4.2. Mexico next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.4.3. Target disease prevalence
    • 9.2.4.4. Competitive scenario
    • 9.2.4.5. Regulatory framework
    • 9.2.4.6. Reimbursement scenario
• 9.3. Europe
  • 9.3.1. Europe Next Generation Sequencing market, 2021 - 2033 (USD Million)
  • 9.3.2. Germany
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Germany next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.2.3. Target disease prevalence
    • 9.3.2.4. Competitive scenario
    • 9.3.2.5. Regulatory framework
    • 9.3.2.6. Reimbursement scenario
  • 9.3.3. UK
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. UK next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.3.3. Target disease prevalence
    • 9.3.3.4. Competitive scenario
    • 9.3.3.5. Regulatory framework
    • 9.3.3.6. Reimbursement scenario
  • 9.3.4. France
    • 9.3.4.1. Key country dynamics
    • 9.3.4.2. France next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.4.3. Target disease prevalence
    • 9.3.4.4. Competitive scenario
    • 9.3.4.5. Regulatory framework
    • 9.3.4.6. Reimbursement scenario
  • 9.3.5. Italy
    • 9.3.5.1. Key country dynamics
    • 9.3.5.2. Italy next generation sequencing (NGS) market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.5.3. Target disease prevalence
    • 9.3.5.4. Competitive scenario
    • 9.3.5.5. Regulatory framework
    • 9.3.5.6. Reimbursement scenario
  • 9.3.6. Spain
    • 9.3.6.1. Key country dynamics
    • 9.3.6.2. Spain next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.6.3. Target disease prevalence
    • 9.3.6.4. Competitive scenario
    • 9.3.6.5. Regulatory framework
    • 9.3.6.6. Reimbursement scenario
  • 9.3.7. Denmark
    • 9.3.7.1. Key country dynamics
    • 9.3.7.2. Denmark next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.7.3. Target disease prevalence
    • 9.3.7.4. Competitive scenario
    • 9.3.7.5. Regulatory framework
    • 9.3.7.6. Reimbursement scenario
  • 9.3.8. Sweden
    • 9.3.8.1. Key country dynamics
    • 9.3.8.2. Sweden next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.8.3. Target disease prevalence
    • 9.3.8.4. Competitive scenario
    • 9.3.8.5. Regulatory framework
    • 9.3.8.6. Reimbursement scenario
  • 9.3.9. Norway
    • 9.3.9.1. Key country dynamics
    • 9.3.9.2. Norway next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.9.3. Target disease prevalence
    • 9.3.9.4. Competitive scenario
    • 9.3.9.5. Regulatory framework
    • 9.3.9.6. Reimbursement scenario
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific next generation sequencing market, 2021 - 2033 (USD Million)
  • 9.4.2. Japan
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Japan next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.4.2.3. Target disease prevalence
    • 9.4.2.4. Competitive scenario
    • 9.4.2.5. Regulatory framework
    • 9.4.2.6. Reimbursement scenario
  • 9.4.3. China
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. China next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.4.3.3. Target disease prevalence
    • 9.4.3.4. Competitive scenario
    • 9.4.3.5. Regulatory framework
    • 9.4.3.6. Reimbursement scenario
  • 9.4.4. India
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. India next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.4.4.3. Target disease prevalence
    • 9.4.4.4. Competitive scenario
    • 9.4.4.5. Regulatory framework
    • 9.4.4.6. Reimbursement scenario
  • 9.4.5. South Korea
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. South Korea next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.4.5.3. Target disease prevalence
    • 9.4.5.4. Competitive scenario
    • 9.4.5.5. Regulatory framework
    • 9.4.5.6. Reimbursement scenario
  • 9.4.6. Australia
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Australia next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.4.6.3. Target disease prevalence
    • 9.4.6.4. Competitive scenario
    • 9.4.6.5. Regulatory framework
    • 9.4.6.6. Reimbursement scenario
  • 9.4.7. Thailand
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Thailand next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.4.7.3. Target disease prevalence
    • 9.4.7.4. Competitive scenario
    • 9.4.7.5. Regulatory framework
    • 9.4.7.6. Reimbursement scenario
• 9.5. Latin America
  • 9.5.1. Latin America next generation sequencing market, 2021 - 2033 (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Brazil next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.5.2.3. Target disease prevalence
    • 9.5.2.4. Competitive scenario
    • 9.5.2.5. Regulatory framework
    • 9.5.2.6. Reimbursement scenario
  • 9.5.3. Argentina
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Argentina next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.5.3.3. Target disease prevalence
    • 9.5.3.4. Competitive scenario
    • 9.5.3.5. Regulatory framework
    • 9.5.3.6. Reimbursement scenario
• 9.6. MEA
  • 9.6.1. MEA next generation sequencing market, 2021 - 2033 (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. South Africa next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.6.2.3. Target disease prevalence
    • 9.6.2.4. Competitive scenario
    • 9.6.2.5. Regulatory framework
    • 9.6.2.6. Reimbursement scenario
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Saudi Arabia next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.6.3.3. Target disease prevalence
    • 9.6.3.4. Competitive scenario
    • 9.6.3.5. Regulatory framework
    • 9.6.3.6. Reimbursement scenario
  • 9.6.4. UAE
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. UAE next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.6.4.3. Target disease prevalence
    • 9.6.4.4. Competitive scenario
    • 9.6.4.5. Regulatory framework
    • 9.6.4.6. Reimbursement scenario
  • 9.6.5. Kuwait
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Kuwait next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.6.5.3. Target disease prevalence
    • 9.6.5.4. Competitive scenario
    • 9.6.5.5. Regulatory framework
    • 9.6.5.6. Reimbursement scenario

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2025
• 10.4. Company Profiles/Listing
  • 10.4.1. Illumina
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. F. Hoffman-La Roche Ltd.
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. QIAGEN
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Thermo Fisher Scientific, Inc.
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. Bio-Rad Laboratories, Inc.
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Oxford Nanopore Technologies
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Revvity, Inc.
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. PacBio
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Merk KGaA
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. BGI
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives